ADD-17014

ADD-17014 is a L-Glu antagonist. ADD-17014 impairs presynaptic excitatory amino acid L-Glu neurotransmission. ADD-17014 is a prodrug of its β-amino alcohol metabolite, and the metabolite acts as a NMDA receptor antagonist by binding to the MK-801 site located inside the NMDA receptor or ion channel. ADD-17014 has an anticonvulsant and anti-ischemic activity. ADD-17014 can be used for neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease and stroke research[1][2].

55643-87-3

12352005

H302-H315-H319-H335

MGluR

GPCR/G Protein; Neuronal Signaling

Neuroscience-Neurodegeneration

Neurological Disease

ClC1=CC=C(N2N=NCC2C3=CC=NC=C3)C=C1

C13H11ClN4

258.71

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

[1]Van der Schyf CJ, Gal S, et al. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs. 2006 Aug;15 (8) :873-86. |[2]Kadaba PK. Rational drug design and the discovery of the delta2-1,2,3-triazolines, a unique class of anticonvulsant and antiischemic agents. Curr Med Chem. 2003 Oct;10 (20) :2081-108.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19021/

Reference compound1

No Development Reported